# US 11,896,676 B2 · Targeting cancer cells and tissue using filamentous plant virus particles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,896,676 B2
- Document ID: US11896676B2
- Status: Granted
- Kind: B2
- Application number: 16/988,210
- Filed: 2020-08-07
- Published: 2021-02-11
- Granted: 2024-02-13
- Earliest claimed: 2019-08-07
- Assignees: Case Western Reserve University
- Applicants: Case Western Reserve University
- Inventors: Nicole F. Steinmetz; Sourabh Shukla
- Web page: https://patentgrep.com/patent/US11896676B2

## CPC

- A61K 47/6901: {Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}
- A61K 49/0097: {Cells, viruses, ghosts, red blood cells, viral vectors, used for imaging or diagnosis in vivo}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0031: {Rectum, anus}
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K 9/0043: {Nose}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/5107: {Excipients; Inactive ingredients}
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 49/0032: {Methine dyes, e.g. cyanine dyes}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A pepino mosaic virus (PepMV) carrier comprising a PepMV particle that has been modified to carry an imaging agent or anticancer agent is described. The PepMV carrier can be used in a method of targeting cancer cells and tissue by administering it to a subject. Cancer tissue targeted by the PepMV carrier can be imaged using an imaging agent, or treated using an anticancer agent.

## Claims

### Claim 1

A method of targeting cancer tissue in a subject, comprising administering to the subject a pepino mosaic virus (PepMV) carrier comprising a PepMV particle modified to carry an imaging agent or a cytotoxic compound,
wherein the PepMV carrier targets cancer tissue selected from the group consisting of triple negative breast cancer (TNBC) tissue or ovarian cancer tissue and has increased tumor homing to triple negative breast cancer (TNBC) tissue and to ovarian cancer tissue compared to a potato virus X (PVX) carrier,
wherein the PepMV carrier is administered via systemic or intraperitoneal (i.p.) administration, and
wherein the PepMV carrier has 1.5-fold increase in tumor homing in triple negative breast cancer (TNBC) tumors and 2-fold increase in tumor homing in ovarian cancer tumors compared to a potato virus X (PVX) carrier.

### Claim 2 (depends on 1)

The method of claim 1, wherein the PepMV carrier has been PEGylated.

### Claim 3 (depends on 1)

The method of claim 1, wherein the PepMV particle comprises an imaging agent.

### Claim 4 (depends on 3)

The method of claim 3, wherein the imaging agent is a fluorescent molecule for fluorescent imaging.

### Claim 5 (depends on 4)

The method of claim 4, wherein the imaging agent is Cy5.

### Claim 6 (depends on 3)

The method of claim 3, wherein an effective amount of a PepMV carrier is administered, and further comprising the step of imaging cancer tissue in the subject using an imaging device subsequent to administering the PepMV carrier.

### Claim 7 (depends on 1)

The method of claim 1, wherein the PepMV virus particle comprises an anti-cancer compound.

### Claim 8 (depends on 7)

The method of claim 7, wherein the anti-cancer agent is an antitumor agent.

### Claim 9 (depends on 1)

The method of claim 1, wherein the cancer tissue is triple negative breast cancer (TNBC) tissue.

### Claim 10

A method of treating cancer in a subject identified as having cancer by administering to the subject a therapeutically effective amount of a pepino mosaic virus (PepMV) carrier comprising a PepMV particle modified to carry an anticancer agent,
wherein the PepMV carrier targets cancer tissue selected from the group consisting of ovarian cancer or triple negative breast cancer (TNBC) and has increased tumor homing to triple negative breast cancer (TNBC) tumors and to ovarian cancer tumors compared to a potato virus X (PVX) carrier,
wherein the PepMV carrier is administered via systemic or intraperitoneal (i.p.) administration, and
wherein the PepMV carrier has 1.5-fold increase in tumor homing in triple negative breast cancer (TNBC) tumors and 2-fold increase in tumor homing in ovarian cancer tumors compared to a potato virus X (PVX) carrier.

### Claim 11 (depends on 10)

The method of claim 10, wherein the PepMV carrier has been PEGylated.

### Claim 12 (depends on 10)

The method of claim 10, wherein the anticancer agent is an antitumor agent.

### Claim 13 (depends on 10)

The method of claim 10, wherein the cancer is triple negative breast cancer (TNBC).

### Claim 14 (depends on 10)

The method of claim 10, wherein the PepMV carrier is administered together with a pharmaceutically acceptable carrier.